Shane Cooke Sells 3,300 Shares of Alkermes Plc (ALKS) Stock

Alkermes Plc (NASDAQ:ALKS) insider Shane Cooke sold 3,300 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $60.00, for a total transaction of $198,000.00. Following the completion of the transaction, the insider now owns 76,408 shares of the company’s stock, valued at $4,584,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shane Cooke also recently made the following trade(s):

  • On Friday, January 26th, Shane Cooke sold 1,700 shares of Alkermes stock. The stock was sold at an average price of $60.02, for a total transaction of $102,034.00.
  • On Thursday, January 11th, Shane Cooke sold 6,207 shares of Alkermes stock. The stock was sold at an average price of $60.22, for a total transaction of $373,785.54.

Shares of Alkermes Plc (NASDAQ:ALKS) opened at $57.29 on Wednesday. The stock has a market cap of $8,810.00, a price-to-earnings ratio of -51.61 and a beta of 2.13. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05. Alkermes Plc has a 12 month low of $46.42 and a 12 month high of $63.40.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. Alkermes’s revenue was up 20.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.09) earnings per share. equities analysts forecast that Alkermes Plc will post -0.59 EPS for the current year.

A number of equities analysts recently weighed in on the stock. BidaskClub lowered shares of Alkermes from a “hold” rating to a “sell” rating in a research report on Saturday, January 20th. Barclays lowered shares of Alkermes from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. JPMorgan Chase & Co. set a $78.00 target price on shares of Alkermes and gave the stock a “buy” rating in a research report on Friday, October 27th. ValuEngine upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Citigroup set a $62.00 target price on shares of Alkermes and gave the stock a “hold” rating in a research report on Thursday, October 26th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $63.33.

A number of institutional investors have recently added to or reduced their stakes in ALKS. Prudential Financial Inc. raised its stake in Alkermes by 5.0% during the second quarter. Prudential Financial Inc. now owns 9,095 shares of the company’s stock valued at $527,000 after purchasing an additional 430 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Alkermes by 950.1% during the second quarter. JPMorgan Chase & Co. now owns 47,526 shares of the company’s stock valued at $2,756,000 after purchasing an additional 43,000 shares in the last quarter. Alliancebernstein L.P. raised its stake in Alkermes by 1.3% during the second quarter. Alliancebernstein L.P. now owns 98,140 shares of the company’s stock valued at $5,689,000 after purchasing an additional 1,275 shares in the last quarter. Teachers Advisors LLC raised its stake in Alkermes by 8.8% during the second quarter. Teachers Advisors LLC now owns 169,027 shares of the company’s stock valued at $9,798,000 after purchasing an additional 13,716 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Alkermes by 0.9% during the second quarter. Northern Trust Corp now owns 854,816 shares of the company’s stock valued at $49,554,000 after purchasing an additional 7,845 shares in the last quarter. 99.58% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Shane Cooke Sells 3,300 Shares of Alkermes Plc (ALKS) Stock” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/31/shane-cooke-sells-3300-shares-of-alkermes-plc-alks-stock.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply